{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:16:57Z","timestamp":1778591817407,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["HTA 15\/58\/18"],"award-info":[{"award-number":["HTA 15\/58\/18"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jval.2020.12.012","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T04:17:44Z","timestamp":1615522664000},"page":"780-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events"],"prefix":"10.1016","volume":"24","author":[{"given":"Edna","family":"Keeney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicky J.","family":"Welton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Dalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah M.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Phillippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus R.","family":"Munaf\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyla H.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7257","key":"10.1016\/j.jval.2020.12.012_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bmj.321.7257.323","article-title":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","volume":"321","author":"Peto","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1308383","article-title":"Global effects of smoking, of quitting, and of taxing tobacco","volume":"370","author":"Jha","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.12.012_bib3","series-title":"Statistics on Smoking: England, 2019","year":"2019"},{"key":"10.1016\/j.jval.2020.12.012_bib4","series-title":"Cost of smoking to the NHS in England: 2015","year":"2017"},{"issue":"4","key":"10.1016\/j.jval.2020.12.012_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/tc.2008.026294","article-title":"The burden of smoking-related ill health in the UK","volume":"18","author":"Allender","year":"2009","journal-title":"Tob Control"},{"key":"10.1016\/j.jval.2020.12.012_bib6","series-title":"The Economics of Tobacco","year":"2017"},{"key":"10.1016\/j.jval.2020.12.012_bib7","series-title":"NICE guideline [NG92] stop smoking interventions and services","year":"2018"},{"key":"10.1016\/j.jval.2020.12.012_bib8","series-title":"Use of e-cigarettes (vapourisers) among adults in Great Britain","year":"2018"},{"issue":"4","key":"10.1016\/j.jval.2020.12.012_bib9","first-page":"2","article-title":"Varenicline: adverse psychiatric reactions, including depression","volume":"2","year":"2008","journal-title":"Drug Safety Update"},{"issue":"10037","key":"10.1016\/j.jval.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ntr\/ntz072","article-title":"Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders","volume":"22","author":"Taylor","year":"2019","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.jval.2020.12.012_bib15","series-title":"Guide to the methods of technology appraisal","year":"2013"},{"issue":"33","key":"10.1016\/j.jval.2020.12.012_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18330","article-title":"What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation","volume":"18","author":"Leaviss","year":"2014","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/tc.10.1.55","article-title":"Development of the health and economic consequences of smoking interactive model","volume":"10","author":"Orme","year":"2001","journal-title":"Tob Control"},{"issue":"10","key":"10.1016\/j.jval.2020.12.012_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/11317730-000000000-00000","article-title":"Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis","volume":"29","author":"Annemans","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1185\/030079908X242917","article-title":"Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands","volume":"24","author":"Hoogendoorn","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.jval.2020.12.012_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1185\/03007990903542666","article-title":"Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers","volume":"26","author":"Linden","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 3","key":"10.1016\/j.jval.2020.12.012_bib21","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1111\/j.1524-4733.2009.00631.x","article-title":"Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea","volume":"12","author":"Bae","year":"2009","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2020.12.012_bib22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2753.2008.01045.x","article-title":"Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence","volume":"15","author":"Bolin","year":"2009","journal-title":"J\u00a0Eval Clin Pract"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurpub\/ckp075","article-title":"Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries","volume":"19","author":"Bolin","year":"2009","journal-title":"Eur J Public Health"},{"issue":"5","key":"10.1016\/j.jval.2020.12.012_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.rmed.2007.12.018","article-title":"Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003","volume":"102","author":"Bolin","year":"2008","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00019053-200826060-00004","article-title":"Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers","volume":"26","author":"Howard","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2020.12.012_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1524-4733.2009.00672.x","article-title":"The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model","volume":"13","author":"Knight","year":"2010","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2020.12.012_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1524-4733.2009.00612.x","article-title":"Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries","volume":"13","author":"Vemer","year":"2010","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib28","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ije\/dyx109","article-title":"The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records","volume":"46","author":"Taylor","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jval.2020.12.012_bib29","unstructured":"Thomas KH DM, L\u00f3pez-L\u00f3pez JA, Keeney E, et\u00a0al. How do smoking cessation medicines compare with respect to their effectiveness and safety: a systematic review, network meta-analysis and cost effectiveness analysis. Health Technol Assess Rep. In press."},{"issue":"10","key":"10.1016\/j.jval.2020.12.012_bib30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2213-2600(15)00320-3","article-title":"Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study","volume":"3","author":"Kotz","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jval.2020.12.012_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS \u2014 a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Statistics and Computing"},{"key":"10.1016\/j.jval.2020.12.012_bib32","series-title":"Population estimates for UK, England and Wales, Scotland and Northern Ireland, mid-2016","year":"2017"},{"key":"10.1016\/j.jval.2020.12.012_bib33","series-title":"Deaths by single year of age, UK, 2016","year":"2016"},{"issue":"3","key":"10.1016\/j.jval.2020.12.012_bib34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/ntr\/ntv079","article-title":"Relapse-prevention booklets as an adjunct to a tobacco quitline: a randomized controlled effectiveness trial","volume":"18","author":"Unrod","year":"2016","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.jval.2020.12.012_bib35","series-title":"Statistics on smoking: England","author":"NHS","year":"2017"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib36","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1164\/ajrccm.159.6.9809042","article-title":"Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City","volume":"159","author":"Cassino","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jval.2020.12.012_bib37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ntr\/ntq175","article-title":"Long-term smoking relapse: a study using the british household panel survey","volume":"12","author":"Hawkins","year":"2010","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14622200110098428","article-title":"Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study","volume":"4","author":"Krall","year":"2002","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.jval.2020.12.012_bib39","series-title":"Health technology assessment (HTA) of smoking cessation interventions","year":"2017"},{"key":"10.1016\/j.jval.2020.12.012_bib40","series-title":"CVD Statistics","year":"2014"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/2396987317746516","article-title":"The economic burden of stroke care in England, Wales and Northern Ireland: using a national stroke register to estimate and report patient-level health economic outcomes in stroke","volume":"3","author":"Xu","year":"2018","journal-title":"Eur Stroke J"},{"issue":"7","key":"10.1016\/j.jval.2020.12.012_bib42","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1017\/S0033291713002067","article-title":"Modelling the cost-effectiveness of preventing major depression in general practice patients","volume":"44","author":"Hunter","year":"2014","journal-title":"Psychol Med"},{"key":"10.1016\/j.jval.2020.12.012_bib43","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jval.2020.12.012_bib44","series-title":"February 2019: monthly exchange rates","author":"Customs","year":"2019"},{"issue":"5","key":"10.1016\/j.jval.2020.12.012_bib45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2020.12.012_bib46","first-page":"113","article-title":"Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer","volume":"21","author":"Bertranou","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.12.012_bib47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.rmed.2007.11.016","article-title":"Use of a preference-based measure of health (EQ-5D) in COPD and asthma","volume":"102","author":"Pickard","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1016\/j.jval.2020.12.012_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152030","article-title":"Multivariate meta-analysis of preference-based quality of life values in coronary heart disease","volume":"11","author":"Stevanovic","year":"2016","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/01.STR.0000196990.69412.fb","article-title":"Long-term outcome after stroke: evaluating health-related quality of life using utility measurements","volume":"37","author":"Haacke","year":"2006","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jval.2020.12.012_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3132\/pcrj.2007.00002","article-title":"The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK","volume":"16","author":"Lloyd","year":"2007","journal-title":"Prim Care Respir J"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib51","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1017\/S0033291703008183","article-title":"Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach","volume":"33","author":"Byford","year":"2003","journal-title":"Psychol Med"},{"key":"10.1016\/j.jval.2020.12.012_bib52","series-title":"NICE guide to the methods of technology appraisal","author":"Earnshaw","year":"2008"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hec.3884","article-title":"Beyond the cost-effectiveness acceptability curve: the appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal","volume":"28","author":"Epstein","year":"2019","journal-title":"Health Econ"},{"issue":"6","key":"10.1016\/j.jval.2020.12.012_bib54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9","article-title":"An economic approach to clinical trial design and research priority-setting","volume":"5","author":"Claxton","year":"1996","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.12.012_bib55","series-title":"Accelerated Value of Information Release, version 2.0.8","year":"2015"},{"key":"10.1016\/j.jval.2020.12.012_bib56","series-title":"Gaussian Processes in Machine Learning. Summer School on Machine Learning","year":"2003"},{"issue":"5","key":"10.1016\/j.jval.2020.12.012_bib57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ijcp.12363","article-title":"The long-term cost-effectiveness of varenicline (12-week standard course and 12\u00a0+ 12-week extended course) vs other smoking cessation strategies in Canada","volume":"68","author":"von Wartburg","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"8","key":"10.1016\/j.jval.2020.12.012_bib58","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.clinthera.2012.07.002","article-title":"Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece","volume":"34","author":"Athanasakis","year":"2012","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.jval.2020.12.012_bib59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/add.14829","article-title":"Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial","volume":"115","author":"Li","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.12.012_bib60","series-title":"Health technology assessment (HTA) of smoking cessation interventions","year":"2017"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:59:03Z","timestamp":1778590743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1098301521000541"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.12.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}